Abstract
The expanding availability of different potent antiviral agents for the treatment of chronic hepatitis B (CHB) has created optimism for achieving treatment goals, such as the loss of serum hepatitis B surface antigen (HBsAg), which represents the closest-to-cure outcome of chronic hepatitis B virus infection. Recent studies indicated the potential usefulness of HBsAg quantification during antiviral therapy (especially with interferon-α-based regimens) as a potential predictor of virologic response. This article critically reviews the most recent data regarding the value of measurements of HBsAg concentrations in predicting response in patients with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative CHB treated with different antiviral agents.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call